Lantern Pharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10–K Summary
Not applicable.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Lantern Pharma Inc., | ||
| A Delaware Corporation | ||
| Dated: March 30, 2026 | By: | /s/ Panna Sharma |
|---|---|---|
| Panna Sharma, Chief Executive Officer | ||
| Dated: March 30, 2026 | By: | /s/ David R. Margrave |
| David R. Margrave, Chief Financial Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Panna Sharma | President, Chief Executive Officer and Director | March 30, 2026 |
| Panna Sharma | (Principal Executive Officer) | |
| /s/ David R. Margrave | Chief Financial Officer | March 30, 2026 |
| David R. Margrave | (Principal Financial and Principal Accounting Officer) | |
| /s/ Donald J. Keyser | Chairman of the Board | |
| Donald J. Keyser | March 30, 2026 | |
| /s/ Maria Maccecchini | Director | |
| Maria Maccecchini | March 30, 2026 | |
| /s/ David S. Silberstein | Director | |
| David S. Silberstein | March 30, 2026 | |
| /s/ Vijay Chandru | Director | |
| Vijay Chandru | March 30, 2026 | |
| /s/ Lee Schalop | Director | |
| Lee Schalop | March 30, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.